Nothing but chutzpah

Nothing but chutzpah

Over the years Diabetic Investor has written about far too many companies that have duped investors. First came the non-invasive group, this was supposed to the Holy Grail of glucose monitoring the answer to everyone’s payers. Next, came non-invasive with a twist as now these charlatans were touting non-invasive CGM. The common thread has always been non-invasive with the added benefit that none and we do mean none of these efforts ever paid off . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.